Balyasny Asset Management
LABP

Balyasny Asset Management’s Landos Biopharma, Inc. Common Stock LABP Stock Holding History

Balyasny Asset Management’s Portfolio LABP Stock Details LABP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,569
Closed -$10K – 3384
2022
Q3 		$10K Buy
+1,569
New +$13.6K ﹤0.01% 2651

Other funds holding LABP

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
SGCA
Steel Grove Capital Advisors Memphis, Tennessee $949M AUM 23.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Balyasny Asset Management's LABP Position: Q4 2022 in Review

Balyasny Asset Management sold out of Landos Biopharma, Inc. Common Stock (LABP) in Q4 2022, closing a stake of 1,569 shares — an estimated $10K sold.

Balyasny Asset Management first reported a position in LABP in Q3 2022 and held it in 1 quarter. The position peaked at $10K in Q3 2022. 23 funds tracked by Wall St. Rank hold LABP as of Q4 2022.

  • Balyasny Asset Management reported no remaining Landos Biopharma, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Balyasny Asset Management sold 1,569 Landos Biopharma, Inc. Common Stock shares in Q4 2022, an estimated $10K.
  • Balyasny Asset Management first reported a position in Landos Biopharma, Inc. Common Stock in Q3 2022 and held it in 1 quarter.
  • Balyasny Asset Management's Landos Biopharma, Inc. Common Stock position peaked at $10K in Q3 2022.
  • 23 funds tracked by Wall St. Rank held Landos Biopharma, Inc. Common Stock as of Q4 2022.

Based on Balyasny Asset Management's 13F filing for Q4 2022, filed 14 Feb 2023.